GLS-5700 in Dengue Virus-Naïve Adults
Public ClinicalTrials.gov record NCT02809443. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus. ZIKA-001 is the first in man clinical trial of this vaccine which encodes for the premembrane-membrane and envelope regions of Zika virus.
Study identification
- NCT ID
- NCT02809443
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 40 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2016
- Primary completion
- Oct 31, 2017
- Completion
- Nov 30, 2017
- Last update posted
- Dec 23, 2024
2016 – 2017
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Miami Research Associate | Miami | Florida | 33143 | — |
| University of Pennslyvania | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Healthy trials
Other public records listing Healthy. Sorted by last update posted; newest first. Not a recommendation.
- NCT07792941: A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20 Not yet recruiting
- NCT07748351: A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007) Not yet recruiting
- NCT07776665: A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044) Recruiting
- NCT07595263: A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) Not yet recruiting
- NCT07677163: A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007) Recruiting
- NCT07767487: A Study of LY4226695 in Healthy Participants Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02809443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 23, 2024 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02809443 live on ClinicalTrials.gov.